BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate if multiple (up to four) intravenous injections of
Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer
patients with bone dominant disease who have progressed on endocrine therapy and are no
longer considered suitable for endocrine therapy. In addition the safety of Xofigo
(Alpharadin) will be assessed.